Secarna Pharmaceuticals to collaborate with Guangzhou’s Sun Yat-sen University to develop a treatment for COVID-19

Secarna Pharmaceuticals have announced that it has entered into a cooperation with the First Affiliated Hospital at Guangzhou Sun Yat-sen University (SYSU) for the development of a treatment or prophylactic for SARS-CoV-2 viral infections. Under this agreement, Secarna will employ its proprietary LNAplusTM platform to develop antisense oligonucleotides (ASOs) which specifically suppress the expression of a certain host factor that is essential for the viral infection cycle.

Secarna’s approach to target host factors is beneficial compared to other approaches targeting the virus directly, as most viruses are known to evade targeted therapies by mutation over time. This risk could be completely avoided by targeting host factors. Additionally, different viruses often depend on common host factors. Therefore, a therapy addressing a host factor linked to existing or emerging viruses could potentially also serve as a treatment against future challenges.

The feasibility of Secarna’s concept was already successfully demonstrated in 20191. In this study, Secarna employed its LNAplusTM platform to develop ASOs targeting the host factor NPC1 to efficiently reduce Ebola virus infection in vitro. The approach’s applicability to SARS-CoV-2 is currently being evaluated by Prof. Claus Bachert at the University of Ghent in Belgium and the First Affiliated Hospital at Guangzhou Sun Yat-sen University (SYSU).

“We are very excited to be working together with Guangzhou’s Sun Yat-sen University and leveraging our proprietary technology to develop LNAplusTM-based ASOs to potentially tackle SARS-CoV-2 infections. By targeting a host factor essential to the viral infection cycle, we hope to prevent the infection of cells and viral spread,” said Jonas Renz, Managing Director and Co-founder of Secarna Pharmaceuticals.

Prof. Claus Bachert added: “This international cooperation is combining an innovative development platform with specific translational laboratory skills and the access to patients in a unique way.”

Want more of the latest sciences news straight to your inbox? Become a SelectScience member for free today>>